Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study
| Status: | Recruiting |
|---|---|
| Conditions: | Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 6 - 16 |
| Updated: | 4/21/2016 |
| Start Date: | July 2015 |
| Contact: | Katie Gordon, MD |
| Email: | katherineagordon@gmail.com |
| Phone: | 407-716-5105 |
The purpose of this study is to investigate topical treatment with Veregen™ 15% ointment as
a single therapeutic agent and compare it to combination therapy with Veregen ™ 15% ointment
and a single destructive treatment by cryotherapy for non-facial verruca vulgaris in the
pediatric population. The investigators will compare the single and combination treatment
modalities over identical time points in patients with non-facial verruca vulgaris. One of
the current options for care for non-facial verruca includes cryotherapy, which is a painful
and destructive method performed in the pediatric dermatology clinic. This study aims to
establish the safety, non-invasivenature, efficiency, and efficacy of Veregen ™ 15% ointment
as monotherapyfor non-facial verruca vulgaris in the pediatric population. The investigators
hypothesize that Veregen ™ 15% ointment monotherapy will non-invasively treat non-facial
verruca vulgaris with similar efficacy as combination therapy with a single cryotherapy
treatment followed by topical application of Veregen ™ ointment. This novel treatment
modality will be useful in the pediatric dermatology community offering a less invasive,
painless option for treatment of non-facial verruca vulgaris.
a single therapeutic agent and compare it to combination therapy with Veregen ™ 15% ointment
and a single destructive treatment by cryotherapy for non-facial verruca vulgaris in the
pediatric population. The investigators will compare the single and combination treatment
modalities over identical time points in patients with non-facial verruca vulgaris. One of
the current options for care for non-facial verruca includes cryotherapy, which is a painful
and destructive method performed in the pediatric dermatology clinic. This study aims to
establish the safety, non-invasivenature, efficiency, and efficacy of Veregen ™ 15% ointment
as monotherapyfor non-facial verruca vulgaris in the pediatric population. The investigators
hypothesize that Veregen ™ 15% ointment monotherapy will non-invasively treat non-facial
verruca vulgaris with similar efficacy as combination therapy with a single cryotherapy
treatment followed by topical application of Veregen ™ ointment. This novel treatment
modality will be useful in the pediatric dermatology community offering a less invasive,
painless option for treatment of non-facial verruca vulgaris.
Inclusion Criteria:
- Male or female of any ethnic background
- Age between 6 years old and 16 years old
- A clinical diagnosis of non-facial verruca vulgaris
- Able to adhere to study visit schedule, Veregen ™ treatment requirements, and
baseline cryotherapy treatment in half of patients
- Verruca size greater than 5 mm
Exclusion Criteria:
- Medically unstable patients
- Patients with immunosuppression
- Families who decline participation
- Verruca may not have been treated in preceding 4 weeks prior to enrollment
- Verruca may not be located on the face or genitalia
- Verruca size less than 5 mm
We found this trial at
1
site
Click here to add this to my saved trials
